0
Abstract: Poster Presentations |

LONG-TERM OUTCOME FOLLOWING LUNG TRANSPLANTATION FOR PATIENTS WITH SARCOIDOSIS FREE TO VIEW

Amit Gaggar, MD*; Keith Wille, MD; Kevin Leon, MD; Katherine Hart, BS; Susan Kerkhof, RN; David McGiffin, MD; K. R. Young, MD
Author and Funding Information

University of Alabama at Birmingham, Birmingham, AL


Chest


Chest. 2005;128(4_MeetingAbstracts):341S-b-342S. doi:10.1378/chest.128.4_MeetingAbstracts.341S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  End-stage sarcoidosis is characterized by severe pulmonary fibrosis and often poorly responsive to medical therapy. Lung transplantation, therefore, may be the only treatment option. Currently, there are few studies evaluating long-term outcomes following transplantation for these patients. The aim of this investigation is to evaluate the post-transplant morbidity and mortality of patients with sarcoid, compared to recipients transplanted for idiopathic pulmonary fibrosis (IPF).

METHODS:  This study is a retrospective review of all lung transplant recipients at a tertiary care center over a 10-year time period (1994-2004). Data collected include patient demographics, bronchoscopy results, spirometry, development of bronchiolitis obliterans syndrome (BOS), and median survival post-transplantation.

RESULTS:  Over the study period, 300 patients underwent lung transplantation. Fourteen (4.7%) had sarcoidosis and 48 (16.0%) had IPF. Recipients in the sarcoid group were younger (mean age 41.3 versus 55.8 years*) and predominantly female (93% versus 38%*), compared to recipients in the IPF group at the time of transplant (* p < 0.01, Mann-Whitney). Five of 14 (36%) sarcoid patients developed BOS versus 15 of 48 (31%) IPF patients (p=ns). There was no significant difference in the time to BOS onset. Median survival was 1,365 days for the sarcoid group and 1,593 days for the IPF group (Hazard Ratio 1.28 by Kaplan-Meier analysis; [95% CI] 0.55-3.14; p = 0.54).

CONCLUSION:  We observe similar long term outcomes for sarcoid and IPF recipients following lung transplantation.

CLINICAL IMPLICATIONS:  Lung transplantation remains an option for the treatment of end-stage sarcoidosis, as BOS and mortality rates post-transplant are comparable to IPF.

DISCLOSURE:  Amit Gaggar, None.

Wednesday, November 2, 2005

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543